Get the Stockscreener App
3.42
3.95%
0.13
After Hours:
3.39
-0.03
-0.88%
Rocket Pharmaceuticals Inc stock is traded at $3.42, with a volume of 1.11M.
It is up +3.95% in the last 24 hours and down -13.85% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.29
Open:
$3.24
24h Volume:
1.11M
Relative Volume:
0.45
Market Cap:
$370.12M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-1.2436
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
+16.72%
1M Performance:
-13.85%
6M Performance:
+37.90%
1Y Performance:
-75.92%
1-Day Range:
$3.24
$3.45
1-Week Range:
$2.91
$3.45
52-Week Range:
$2.19
$15.00
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.42 | 356.05M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-20-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Class Action Alert: Levi & Korsinsky Reminds Rocket (RCKT) Investors of August 11, 2025 Deadline - The National Law Review
How Rocket Pharmaceuticals Inc. Equity Warrant stock performs in weak economyWeekly Trend Recap & Daily Profit Focused Screening - moha.gov.vn
What is the fair value of Rocket Pharmaceuticals Inc. stock nowInflation Watch & Smart Allocation Stock Reports - moha.gov.vn
Will Rocket Pharmaceuticals Inc. stock deliver consistent dividendsTrade Ideas & High Accuracy Swing Trade Signals - moha.gov.vn
DEADLINE NEXT WEEK: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit (PR Newswire) - Aktiellt
How buybacks impact Rocket Pharmaceuticals Inc. stock valuePortfolio Gains Report & Weekly Hot Stock Watchlists - BỘ NỘI VỤ
Aug Big Picture: How buybacks impact Rocket Pharmaceuticals Inc. stock valueEarnings Overview Summary & Real-Time Volume Analysis Alerts - BỘ NỘI VỤ
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference - Business Wire
Skyline Ventures India Limited Moves Into Bullish Territory Based on MACDIndustrial Stocks Review & Rapid Wealth Accumulation - earlytimes.in
Why Rocket Pharmaceuticals Inc. Equity Warrant stock could be next big winner2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Can Rocket Pharmaceuticals Inc. (9IP1) stock sustain revenue momentum2025 Top Decliners & Intraday High Probability Alerts - newser.com
How Rocket Pharmaceuticals Inc. (9IP1) stock compares with top peersTrade Signal Summary & Technical Pattern Based Signals - newser.com
Is Rocket Pharmaceuticals Inc. stock entering bullish territoryWeekly Trade Summary & AI Enhanced Trade Execution Alerts - newser.com
How Rocket Pharmaceuticals Inc. (9IP1) stock correlates with oil marketsPrice Action & AI Driven Stock Movement Reports - newser.com
Can Rocket Pharmaceuticals Inc. (9IP1) stock retain market dominance2025 Market Overview & Weekly Market Pulse Updates - newser.com
Applying big data sentiment scoring on Rocket Pharmaceuticals Inc. Equity WarrantShare Buyback & AI Powered Market Entry Ideas - newser.com
Using R and stats models for Rocket Pharmaceuticals Inc. forecastingQuarterly Market Summary & Daily Stock Trend Watchlist - newser.com
Rocket Pharmaceuticals CEO Sells Shares - TradingView
CEO Shah Sells 6,276 ($18.7K) Of Rocket Pharmaceuticals Inc [RCKT] - TradingView
[Form 4] ROCKET PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rocket Pharmaceuticals, Inc.Common Stock (Nasdaq:RCKT) Stock Quote - Markets Financial Content
How Rocket Pharmaceuticals Inc. stock reacts to inflationary pressuresWall Street Watch & Safe Capital Growth Tips - newser.com
How Rocket Pharmaceuticals Inc. (9IP1) stock trades after rate cutsJuly 2025 Sentiment & Risk Controlled Stock Pick Alerts - newser.com
Published on: 2025-11-20 03:46:18 - newser.com
Is Rocket Pharmaceuticals Inc. stock oversold or undervalued2025 Risk Factors & Intraday High Probability Alerts - newser.com
RCKT CEO Gaurav Shah discloses November 2025 insider stock sale - Stock Titan
Using data models to predict Rocket Pharmaceuticals Inc. Equity Warrant stock movementJuly 2025 Chart Watch & Free High Return Stock Watch Alerts - newser.com
What dividend safety rating applies to Rocket Pharmaceuticals Inc. (9IP1) stock2025 AllTime Highs & Technical Analysis for Trade Confirmation - newser.com
Is Rocket Pharmaceuticals Inc. (9IP1) stock undervalued after correctionWeekly Volume Report & Free Reliable Trade Execution Plans - newser.com
Why Rocket Pharmaceuticals Inc. (9IP1) stock could be next leader2025 Short Interest & Low Drawdown Investment Strategies - newser.com
Is it time to cut losses on Rocket Pharmaceuticals Inc. Equity WarrantTrade Risk Summary & Weekly High Return Stock Opportunities - newser.com
Risk adjusted return profile for Rocket Pharmaceuticals Inc. analyzedWeekly Volume Report & AI Forecast for Swing Trade Picks - newser.com
Rocket Pharmaceuticals Inc. recovery potential after sell off2025 Institutional Moves & Weekly Watchlist for Hot Stocks - newser.com
How Rocket Pharmaceuticals Inc. stock performs after earningsBuy Signal & Real-Time Volume Surge Alerts - newser.com
Will Rocket Pharmaceuticals Inc. (9IP1) stock see insider accumulationMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
Why Rocket Pharmaceuticals Inc. stock is considered a top pick2025 Performance Recap & AI Driven Stock Reports - newser.com
Heatmap analysis for Rocket Pharmaceuticals Inc. Equity Warrant and competitors2025 Valuation Update & Daily Chart Pattern Signal Reports - newser.com
Is Rocket Pharmaceuticals Inc. (9IP1) stock good for wealth creation2025 Top Decliners & Technical Entry and Exit Alerts - newser.com
Will Rocket Pharmaceuticals Inc. Equity Warrant stock recover after recent drop2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com
What is the fair value of Rocket Pharmaceuticals Inc. Equity Warrant stock nowJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rocket Pharmaceuticals Inc Stock (RCKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shah Gaurav | CEO |
Nov 18 '25 |
Sale |
2.98 |
6,276 |
18,721 |
778,296 |
| Militello John | See Remarks |
Nov 18 '25 |
Sale |
2.98 |
1,086 |
3,240 |
65,920 |
| Wilson Martin | General Counsel |
Nov 18 '25 |
Sale |
2.98 |
1,646 |
4,910 |
383,816 |
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):